Rimassa L - Search Results

1

Combination immunotherapy for hepatocellular carcinoma.

Rimassa L, Finn RS, Sangro B. Rimassa L, et al. J Hepatol. 2023 Aug;79(2):506-515. doi: 10.1016/j.jhep.2023.03.003. Epub 2023 Mar 16. J Hepatol. 2023. PMID: 36933770 Review.

2

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, Carnaghi C, Pedicini V, Giordano L, Santoro A. Personeni N, et al. Among authors: rimassa l. J Hepatol. 2012 Jul;57(1):101-7. doi: 10.1016/j.jhep.2012.02.016. Epub 2012 Mar 10. J Hepatol. 2012. PMID: 22414760

3

Regorafenib for the treatment of unresectable hepatocellular carcinoma.

Rimassa L, Pressiani T, Personeni N, Santoro A. Rimassa L, et al. Expert Rev Anticancer Ther. 2017 Jul;17(7):567-576. doi: 10.1080/14737140.2017.1338955. Epub 2017 Jun 9. Expert Rev Anticancer Ther. 2017. PMID: 28580808 Review.

4

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications.

Personeni N, Pressiani T, Santoro A, Rimassa L. Personeni N, et al. Among authors: rimassa l. Drugs Context. 2018 Jun 27;7:212533. doi: 10.7573/dic.212533. eCollection 2018. Drugs Context. 2018. PMID: 30002715 Free PMC article. Review.

5

Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial.

Rimassa L, Porta C, Borbath I, Daniele B, Finn RS, Raoul JL, Schwartz LH, He AR, Trojan J, Peck-Radosavljevic M, Abbadessa G, Goldberg T, Santoro A, Bruix J. Rimassa L, et al. Hepat Oncol. 2014 Apr;1(2):181-188. doi: 10.2217/hep.14.3. Epub 2014 Jan 29. Hepat Oncol. 2014. PMID: 30190953 Free PMC article. Review.

6

Drugs in Development for Hepatocellular Carcinoma.

Rimassa L. Rimassa L. Gastroenterol Hepatol (N Y). 2018 Sep;14(9):542-544. Gastroenterol Hepatol (N Y). 2018. PMID: 30364332 Free PMC article. No abstract available.

7

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date.

Personeni N, Pressiani T, Rimassa L. Personeni N, et al. Among authors: rimassa l. J Hepatocell Carcinoma. 2019 Jan 31;6:31-39. doi: 10.2147/JHC.S168953. eCollection 2019. J Hepatocell Carcinoma. 2019. PMID: 30775342 Free PMC article. Review.

8

Cabozantinib for the treatment of hepatocellular carcinoma.

Personeni N, Rimassa L, Pressiani T, Smiroldo V, Santoro A. Personeni N, et al. Among authors: rimassa l. Expert Rev Anticancer Ther. 2019 Oct;19(10):847-855. doi: 10.1080/14737140.2019.1674141. Epub 2019 Oct 11. Expert Rev Anticancer Ther. 2019. PMID: 31603008 Review.

9

Targeted agents for second-line treatment of advanced hepatocellular carcinoma.

Personeni N, Pressiani T, Bozzarelli S, Rimassa L. Personeni N, et al. Among authors: rimassa l. World J Gastrointest Oncol. 2019 Oct 15;11(10):788-803. doi: 10.4251/wjgo.v11.i10.788. World J Gastrointest Oncol. 2019. PMID: 31662820 Free PMC article. Review.

10

Molecular therapies for HCC: Looking outside the box.

Faivre S, Rimassa L, Finn RS. Faivre S, et al. Among authors: rimassa l. J Hepatol. 2020 Feb;72(2):342-352. doi: 10.1016/j.jhep.2019.09.010. J Hepatol. 2020. PMID: 31954496 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

284 results

Search Page